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Non-alcoholic fatty liver disease (NAFLD) is a multifactorial condition with a significant genetic 
contribution to its pathogenesis and progression. Over the past decade, there has been much 
investigation into genetic variants associated with NAFLD in adults1 but there have been only a handful 
of studies focusing on children2. In this issue, Hudert et al.3 combines candidate single nucleotide 
polymorphism (SNP) testing with proteomics and computational modelling in a cohort of 70 children 
with biopsy-proven NAFLD to deepen our understanding of these genetic variants. Exploring the role 
of genetic variants in pediatric NAFLD is particularly important due to its unique histology with 
periportal/zone 1-predominant localisation of steatosis and inflammation, which is associated with 
more advanced fibrosis4.
Hudert et al.3 selected 14 SNPs previously associated with adult NAFLD, of which 3 were significantly 
associated with disease in pediatric NAFLD compared to a control group: rs738409C>G in PNPLA3, 
rs1044498A>C in ENPP1 and rs780094C>T in GCKR, but not rs58542926C>T near TM6SF2 or 
rs641738C>T near TMC4-MBOAT7.
When SNP-histology associations were examined, rs738409C>G in PNPLA3 and rs13412852C>T near 
lipin 1 (LPIN1) were significantly associated with the severity of steatosis. Critically, PNPLA3 was 
associated with periportal/zone 1-predominant steatosis (Figure 1). These histological features are 
relatively specific to NAFLD in children, particularly those who are pre-pubertal. The same SNP was 
also associated with an increased risk of progression to fibrosis, along with rs780094C>T in GCKR, 
rs1260326C>T in GCKR, and rs659366C>T near UCP2.
rs738409C>G in PNPLA3 is recognised as the most important genetic variant in NAFLD. Whilst there 
have been some conflicting reports, data from several pediatric studies support these findings (Table 
1). However, this is the first identification of a genetic variant associated with periportal localisation 
of disease. What causes the periportal predominant histology of pediatric NAFLD is unclear. 
Hypotheses have included dietary factors, circulating androgens, and intestinal dysbiosis. It is known 
that zonal hepatocyte specification causes altered lipid accumulation in NAFLD5. It is likely that the 
Ile148Met variant in PNPLA3 is one factor that primes the periportal area for steatosis and lipotoxicity, 
which is exacerbated in the context of obesity and insulin resistance, similar to findings in adults6. 
This is the first study to show a correlation between GCKR rs780094C>T and presence of fibrosis in 
pediatric NAFLD. rs780094C>T in GCKR is well established as a pleomorphic variant associated with 
insulin resistance and multiple metabolic traits7. The group from Berlin went on to perform proteomic 
analysis using mass spectrometry. rs780094C>T was correlated with decreased hepatic GCKR protein. 
GCKR regulates the activity of the glucokinase enzyme by forming an inactive complex with the 
enzyme and transporting it from the cytoplasm to the nucleus; thus, decreased levels of GCKR allow 
increased glucokinase activity. Pathway enrichment analysis linked the GCKR rs780094 T/T genotype 
to altered lipid metabolism and mathematical modelling suggested that increased glucokinase activity 
leads to hepatic fat accumulation, de novo fatty acid synthesis and increased glucose uptake. The same 
variant has been similarly implicated in adult disease, where it has also been associated with increased 
intrahepatic fat accumulation, risk of NAFLD, and fibrosis8. It will be interesting to see whether 
rs780094C>T achieves genome- or exome-wide significance in larger studies of histologic NAFLD, such 
as from the European NAFLD Registry / LITMUS consortium9.
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In this study, proteomics revealed that the PNPLA3 SNP resulted in decreased retinol metabolism and 
decreased hepatic protein levels of retinol dehydrogenase 16 (RDH16), where lower RDH16 levels also 
correlated with the severity of fibrosis. Precisely how this PNPLA3 variant alters retinol metabolism is 
unclear. Retinol is a lipid-soluble nutrient that is stored mostly as retinyl esters in lipid droplets of 
hepatic stellate cells (HSCs). PNPLA3 encodes adiponutrin, an enzyme with retinyl-palmitate lipase 
function that has been shown to cause retinol release from lipid droplets in response to insulin in HSCs 
in vitro and ex vivo10. This retinyl-palmitate lipase function is reduced with the PNPLA3 polymorphism, 
resulting in reduced retinol release from HSCs10. Evidence suggesting that wild-type PNPLA3-mediated 
retinol release reduces secretion of extracellular matrix metalloproteases11 could explain the 
relationship of retinol metabolism and liver fibrosis.
Hudert et al. also confirm that hepatic levels of retinol-binding protein 4 (RBP4) are independently 
associated with fibrosis, while serum RBP4 levels are negatively associated with fibrosis. Studies have 
linked alterations in liver molecular trafficking and protein catabolism in NAFLD and hepatitis C-
associated cirrhosis to accumulation of RBP412. RBP4 was proposed to encourage hepatic steatosis by 
interfering with the RXR-retinol interaction and to act on adipocytes to interfere with insulin 
signalling12. These hypotheses require further evaluation, but could provide some explanation as to 
why PNPLA3 Ile148Met is so strongly associated with fibrosis compared to other genetic variants 
associated with steatosis.
rs72613567T>TA in HSD1713 is the most recently described genetic variant associated with NAFLD13. 
This variant has a protective function, reducing risk of cirrhosis and severity of histological NAFLD. It 
also seems to mitigate the harmful effect of rs738409C>G in PNPLA3. Interestingly, recent data have 
suggested that HSD1713 acts as a lipid droplet retinol dehydrodgenase14. The current study was 
unable to test for this SNP but the combination of these data may provide a mechanism for interaction 
between HSD1713 and PNPLA3 through retinol metabolism.
UCP2 is an inner mitochondrial membrane protein that is expressed in adipose tissue and liver. Akin 
to GCKR, variants in UCP2 have been associated with many metabolic traits including adiposity15, BMI, 
and insulin resistance, in addition to NAFLD16. This is the first study to identify a role in pediatric 
NAFLD. Modelling implicates reduced UCP2 in increased hepatic triacylglycerol storage, as would be 
expected if uncoupling were reduced. Similar data exists for ENPP1, which is known to modulate 
insulin receptor signalling and obesity17, but has relatively little data supporting an effect on NAFLD 
histology. It remains unclear to what extent these variants have a specific effect on NAFLD or reflect 
changes in adipose dysfunction and insulin resistance.
There are some notable differences between this study’s findings and existing literature in adults. 
rs58542926C>T near TM6SF2 has been associated with steatosis and fibrosis progression in adults18. 
This SNP was not associated with histological severity in this current study, perhaps given its low allele 
frequency and the relatively small cohort. Similarly, rs641738C>T near TMC4-MBOAT7 was only 
weakly associated with fibrosis, though some data on this genetic variant in adults is conflicting19. No 
effect was found for rs12137855C>T near LYPLAL1, which had genome-wide significance effect on 
hepatic fat content in adults and rs4240624 G>A near PPP1R3B was not assessed in this cohort20. It 
will be interesting to see in larger studies whether these reflect a true difference in the genetic 
aetiology between pediatric and adult disease.
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Though this study advances our understanding of genetics and histology, it is limited by a small sample 
size, which reduces the number of variables that can be controlled for in analyses. This is a common 
theme pediatric studies as the combination of histology and DNA for genotyping is rarely available. A 
further consideration for these data is the single (tertiary) centre nature of the cohort, which may bias 
the spectrum of histology seen. Therefore, the generalisability of these findings may be limited in 
cohorts of different genetic ancestries.
Summary and future directions
These data complement our understanding of genetic variants in pediatric NAFLD. Firstly, PNPLA3 
has zonal-specific effects on histology, suggesting that this variant primes the periportal region for 
more severe NAFLD in children, but the other factors involved are still unclear. This, and other recent 
data, provide a possible link between PNPLA3 and HSD1713 via retinol metabolism. More 
generally, there are significant differences between genetic variants in children and adults. Whilst 
these may be influenced by sample size and natural history of the disease, these data support the 
notion that the pathophysiology of pediatric NAFLD is, at least partially, distinct from that of adults. 
The results of larger studies, including exome and genome sequencing, will shed further light on 
these questions.
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Figure legends:
Figure 1. Genetic variants associated with zonal-specific histology in pediatric NAFLD. Unlike adult 
NASH, pediatric NAFLD shows periportal predominant histology with a lack of ballooning, particularly 
in pre-pubertal children. Hudert et al3 found common genetic variants in several genes to correlate 
with periportal histological features. Other variants were associated with histology without a zonal 
pattern.
Table legends:
Table 1. Common genetic variants associated with radiological or histological NAFLD in children from 
candidate gene studies and genome-wide association studies. See Supplementary Material for full 
references.
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Gene
Polymorphism Chr: bp Variant(s) Study Population
NAFLD 
assessment 
modality
Results
ACTR5
rs6128907 (T>C)
rs6124026 (A>G)
rs6128918 (G>A)
20: 37387862
20: 37399987
20: 37391432
Intronic Wattacheril et al, 2017
Hispanic boys within NASH Clinical Research 
Network (CRN) sample
Median age: 12.0
n = 208
Biopsy Three variants (rs6128907[C], rs6124026[G], rs6128918[A]) associated with fibrosis
CNR2
rs35761398 (CAA/CGG) 1: 23875429 Q63R Rossi et al, 2012
Italian hospital
Mean age: 10.2
n = 118
Biopsy CB2 Q63R variant associated with severity of inflammation and presence of NASH
ENPP1
rs1044498 (A>C) 6: 131851228 L121G Hudert et al, 2018
Berlin adolescent NAFLD cohort
Age = 10-17
n = 70
Biopsy ENPP1 rs1044498 [C] variant associated with NAFLD
ETS1
rs3935794 (A>G) 11: 128390677 Intronic Wattacheril et al, 2017
Hispanic boys within NASH Clinical Research 
Network (CRN) sample
Median age: 12.0
n = 208
Biopsy ETS1 rs3935794 [G] variant associated with fibrosis
Hudert et al, 2018
Berlin adolescent NAFLD cohort
Age = 10-17
n = 70
Biopsy
GCKR rs780094 [T] variant associated with NAFLD and decreased levels of GCKR 
protein
GCKR rs780094 [T] and rs1260326 [T] variants associated with fibrosis and 
decreased levels of GCKR protein
GCKR
rs780094 (C>T)
rs1260326 (C>T)
(in linkage disequilibrium)
2: 27518370
2: 27508073
P446L
Lin et al, 2014
Obese Taiwanese children
Age = 7-18
n = 797
Ultrasound GCKR rs780094 [T] variant associated with increased risk of NAFLD
IL18RAP
rs11465670 (T>C) 2: 103034440 Wattacheril et al, 2017
Hispanic boys within NASH Clinical Research 
Network (CRN) sample
Median age: 12.0
n = 208
Biopsy IL18RAP rs14465670 [C] variant associated with fibrosis
IRS-1
rs1801278 (A>G) 2: 226795828 G972A Dongiovanni et al, 2010
Italian children
Mean Age = 11
n = 71
Biopsy rs1801278 variant associated with increased risk of fibrosis (however, only 2 patients were staged as F>1)
KLF6
rs3750861 (C/T) 10: 3782241 IVS1-27A Nobili et al 2014
Italian hospital
Age = 6-18
n = 152
Biopsy IVS1-27A variant associated with reduced risk of fibrosis
Valenti et al, 2012
Italian hospital
Mean age: 10.2
n = 142
Biopsy LPIN1 rs13412852 [T] variant associated with reduced NAFLD severity and lower prevalence of fibrosis
LPIN1
rs13412852 (C>T) 2: 11774815 Intronic Hudert et al, 2018
Berlin adolescent NAFLD cohort
Age = 10-17
n = 70
Biopsy LPIN1 rs13412852 [T] variant associated with steatosis
MnSOD
rs4880 (T>C) 6: 159692840 A16V El-Koofy et al, 2018
Egyptian paediatric obesity clinic
Age = 2-15
n = 76
Biopsy NASH patients had a higher incidence of the rs4880 (T) variant
MTP promoter
rs1800591 (G>T) 4: 99574331 El-Koofy et al, 2018
Egyptian paediatric obesity clinic
Age = 2-15
n = 76
Biopsy NASH patients had a higher incidence of the [G] variant
Hudert et al, 2018
Berlin adolescent NAFLD cohort
Age = 10-17
n = 70
Biopsy
PNPLA3 rs738407 [G] variant associated with severity of steatosis, zone 
1/periportal disease and fibrosis
PNPLA3 rs738407 [G] variant associated with decreased retinol metabolism
Rotman et al, 2010
NIH centre patients
Mean age = 12.4
n = 223
Biopsy
No association between PNPLA3 rs738407 [G] variant with histological 
parameters
PNPLA3 rs738407 [G] variant associated with a younger age of presentation
PNPLA3
rs738409 C>G 22: 43928847 I148M
Valenti et al, 2010
Italian hospital
Age: 6-13
n = 149
Biopsy
PNPLA3 rs738409 [G] variant strongly associated with steatosis severity, 
hepatocellular ballooning, lobular inflammation and presence of fibrosis
No association with PNPLA3 and periportal fibrosis
PPARGC1A
rs8192678 (G>A) 4: 23814039
G482S Lin et al, 2013
Taiwanese obese children
Age: 7-18
n = 781
Ultrasound PPARGC1A rs8192678 [A] variant associated with NAFLD
RAB37
rs12942311 (T>C) 17: 72710796 Intronic Wattacheril et al, 2017
Hispanic boys within NASH Clinical Research 
Network (CRN) sample
Median age: 12.0
n = 208
Biopsy RAB37 rs12942311 [C] variant associated with fibrosis
SDK1
rs688020 (T>C) 7: 4228553 Wattacheril et al, 2017
Hispanic boys within NASH Clinical Research 
Network (CRN) sample Biopsy SDK1 rs688020 [C] variant associated with fibrosis
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Median age: 12.0
n = 208
Goffredo et al, 2016
American paediatric obesity clinic
Mean age: 13
n = 454
MRI TM6SF2 rs58542926 [T] variant associated with high hepatic fat content in Caucasians and African Americans, but not Hispanics
TM6SF2
rs58542926 (C>T) 19: 19268740 E167K
Dongiovanni et al, 2015
Patients from four centres: Milan, Palermo, 
Rome, Kuopio
n = 1201
Biopsy
TM6SF2 rs58542926 [T] variant associated with increased risk of NASH, 
advanced fibrosis, increased serum aminotransferase levels, decreased serum 
lipid levels
TNFA promoter
TNF-α -238/rs361525 (G>A)
TNF-α -308/rs1800629 (G>A)
6: 31575324
6: 31575254 Yang et al, 2012
South Korean hospital
n = 111 Biopsy
No association between TNF-α variants and increased risk of NAFLD
Two TNF-α variants (G308A, G238A) associated with insulin resistance
TRAPPC9
rs11166927 (C>T)
rs11166926 (G>A)
rs2242181 (T>C)
rs7836476 (T>C)
8: 140796420
8: 140795752
8: 140819819
8: 140819819
? Wattacheril et al, 2017
Hispanic boys within the NASH Clinical 
Research Network (CRN) sample
Median age: 12.0
n = 208
Biopsy Four TTRAPC9 variants (rs11166927, rs11166926, rs2242181, rs7836476) associated with increased NAS score
UCP2
rs659366 (C>T) 11: 73983709 G866A Hudert et al, 2018
Berlin adolescent NAFLD cohort
Age = 10-17
n = 70
Biopsy UCP2 rs659366 [T] variant associated with fibrosis
UGT1A1
rs4148323 (G>A) 2: 233760498 G71R Lin et al, 2009
Taiwanese obese children
Age: 6-13
n = 234
Ultrasound UGT1A1*6 rs4148323 [A] variant associated with a reduced risk of NAFLD
Table 1. Common genetic variants associated with radiological or histological NAFLD in children from candidate gene studies and genome-wide association studies. See Supplementary Material for full references.
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 Figure 1. Genetic variants associated with zonal-specific histology in pediatric NAFLD. Unlike adult NASH, 
pediatric NAFLD shows periportal predominant histology with a lack of ballooning, particularly in pre-
pubertal children. Hudert et al found common genetic variants in several genes to correlate with periportal 
histological features. Other variants were associated with histology without a zonal pattern. 
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